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Available online 15 October 2016Background:Omentin is relatedwithmetabolic syndrome andobesity. Pancreatic adenocarcinoma (PA) is a lethal
and obesity-linked malignancy. This study was conducted to investigate the serum levels of omentin in patients
with PA and the relationship with tumor progression and known prognostic parameters.
Material and methods: Serum samples were obtained from thirty-three patients on ﬁrst admission before any
treatment. Age, sex and body mass index (BMI) matched 30 healthy controls were included in the analysis.
Both serum omentin levels were measured using enzyme-linked immunosorbent assay (ELISA).
Results: The median age at diagnosis was 59 years (32–84 years). Twenty (61%) patients were men and the re-
maining were women. The most common metastatic site was liver in 23 patients with metastasis (n = 19,
83%). Thirty-nine percent of 23 metastatic patients who received palliative chemotherapy (CTx) were CTx–
responsive. Median overall survival of the whole group was 41.3 ± 8.3 weeks [95% conﬁdence interval (CI) =
25–58weeks]. The baseline serum omentin levels were signiﬁcantly higher in patients with PA than in the control
group (p b 0.001). Serum omentin levels were signiﬁcantly higher in patients with larger pathologic tumor size
compared with smaller size (p= 0.03). Conversely, serum omentin concentrationwas found to have no prognos-
tic role on survival (p = 0.54).
Conclusion: Serum levels of omentin may have a good diagnostic role in patients with PA.arch Hospital
. This is an op© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Serum1. Introduction
Pancreatic adenocarcinoma (PA) is the eighth leading cause of
cancer deaths in men and the ninth in women worldwide. The ma-
jority of these tumors (85%) are adenocarcinomas arising from the
ductal epithelium. Approximately 48.960 patients are diagnosed
with cancer of the exocrine pancreas annually in the United States,
and almost all are expected to die from the disease due to its aggres-
sive nature [1].
The link between high body mass, lack of physical activity, and PC
risk has been illustrated in several studies [2–4]. Several molecular fac-
tors may play an important role in the association between obesity and
cancer, including insulin resistance, aberrant insulin like growth factor
expression, sex hormones disorder and adipocytokines [5]. Currently
adipose tissue is considered as an active endocrine organ with, Istanbul, Turkey.
en access article undermetabolic and immune regulatory roles [6]. Adipose tissue secrets a va-
riety of proteins, including adipokines. Furthermore, adipocytokines
might cause the proliferation and growth of tumor cells, induce inﬂam-
mation and anti-apoptosis pathways, which subsequently can prompt
cancer metastasis [7].
Omentin-1 is a 34-kDa adipocytokine that is primarily secreted
from stromal vascular cells of visceral adipose tissue and enhance in-
sulin sensitivity and glucose metabolism in normal weight individ-
uals. Omentin-1 is considered to play a role in inﬂammatory
responses and cell differentiation, and also promotes apoptosis of
cancer cells [8–10]. In prostate and colorectal carcinoma, serum
omentin levels were found to be high and in renal cell carcinoma it
is found to be decreased [11–14]. In acute and chronic pancreatitis,
the elevation in omentin levels was due to the anti-inﬂammatory ef-
fects of omentin and elevated omentin levels improved insulin resis-
tance, caused a signiﬁcant reduction in glucose levels [15]. In
literature, there is limited data about omentin and cancer relation-
ship. To our knowledge; our study is the only one in pancreatic
carcinoma.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1.
Characteristics of the patients and disease.
Variables n
No. of patients 33
Age (years)
Median (range) 59 (32–84)
Gender
Male/female 20/13
Performance status (PS)a
0/1/2/3 4/19/5/4
Weight lossa
Yes/no 26/4
Jaundicea
Yes/no 9/22
b
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2.1. Patients' characteristics
The data of 33 patients with histologically conﬁrmed diagnosis of PA
were recorded from their medical charts. The staging of metastatic pa-
tients was done by using computed tomography (CT), magnetic reso-
nance imaging (MRI), and positron emission computed tomography
(PET/CT) scan. Patients were staged according to the International
Union Against Cancer TNM classiﬁcation.
Chemotherapy (CTx) was given to the majority of the patients with
metastatic disease (n = 20, 61%). Regimens of single or combination
CTx were selected based on the performance status of patients and ex-
tension of the disease. CTx schemes were applied as follows: combina-
tion of gemcitabine with platinum or capecitabine (n = 6 and n = 3),
or gemcitabine alone (n= 11). Response to treatment was determined
by radiologically after 2–3 cycles of CTx according to revised RECIST
criteria version 1.1. by the investigators and classiﬁed as follows: com-
plete response (CR), partial response (PR), stable disease (SD), or pro-
gressive disease (PD). The tumor response after 2 months of CTx was
used for statistical analysis. Follow-up programs of metastatic disease
consisted of clinical, laboratory, and imaging by using a CT or MRI de-
pending on which imaging methods were used at baseline and per-
formed at 8-week intervals during CTx or every 12 weeks for no
anticancer treatment. Patientswith either PR or SDwere classiﬁed as re-
sponders, and patients with PD were considered non-responders.
The possible prognostic variableswere selected based on those iden-
tiﬁed in previous studies. Serum carcino-embryonic antigen (CEA) and
carbohydrate antigen (CA) 19.9 levels were determined by microparti-
cle enzyme immunoassay (Abbott Diagnostics, Chicago, IL). Serum
erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH)
levels, albumin and, whole blood count assays were measured at pre-
sentation in our biochemical laboratory. Serum LDH activity was deter-
mined immediately after collection by the kinetic method on a Targa-
3000 autoanalyzer (Pointe Scientiﬁc Inc., Lincoln Park, MI, U.S.A.) at
37 °C. The laboratory parameters were evaluated at diagnosis within
the normal ranges of our institution.
For comparison of serum levels of omentin, age, sex and BMI
matched 30 healthy controls were included in the analysis. Blood sam-
ples were obtained from patients with PA at ﬁrst admission before any
treatment. Institutional review board approval was obtained from
each subject prior to the commencement of the study.Surgery type
Whipple surgery/palliative surgery 5/3
Pathologic tumor (pT) sizea
bSmall (b40 mm)/≥ large (≥40 mm) 14/14
Site of lesion
Head/corpus-tail 21/10
Response to chemotherapy (CTx)
Yes (PR + SD)/no (PD) 9/11
Metastasis
Yes/no 23/10
Erythrocyte sedimentation rate (ESH)
Normal (b40/h)/high (N40/h) 11/12
White blood cell count (WBC)a
Normal (b10.000/mm3)/high (N10.000/mm3) 22/9
Hemoglobin (Hb)a
Low (b12 g/dL)/normal (N12 g/dL) 12/19
Platelet count (PLT)a
Low (b150.000/mm3)/normal (N150.000/mm3) 5/26
Lactate dehydrogenase (LDH)a
Normal (b450 IU/L)/high (N450 IU/L) 21/8
Albumina
Low (b4 gr/dL)/normal (N4 gr/dL) 10/17
Carcinoembryonic antigen (CEA)a
Normal (b5 ng/mL)/high (N5 ng/mL) 19/10
Carbohydrate antigen (CA 19.9)a
Normal (b38 U/mL)/high (N38 U/mL) 7/22
a Patients with unknown data concerning the variables are not included in the
analysis.
b In 10 patients with non-metastatic disease.2.2. Measurement of serum omentin levels
This assay is a Sandwich ELISA based on: 1) capture of omentin-1
molecules in the sample by anti-omentin IgG and immobilization of
the resulting complex to the wells of a microtiter plate coated by a
pre-titered amount of anchor antibodies, 2) and the simultaneous bind-
ing of a second biotinylated antibody to omentin-1, 3)wash away of un-
bound materials, followed by conjugation of horseradish peroxidase to
the immobilized biotinylated antibodies, 4) wash-away of free enzyme,
and 5) quantiﬁcation of immobilized antibody-enzyme conjugates by
monitoring horseradish peroxidase activities in the presence of the sub-
strate 3,3′,5,5′-tetra-methylbenzidine. The enzyme activity is measured
spectrophotometrically by the increased absorbency at 450 nm,
corrected from the absorbency at 590 nm, after acidiﬁcation of formed
products. Since the increase in absorbency is directly proportional to
the amount of captured omentin-1 in the unknown sample, the concen-
tration of omentin-1 can be derived by interpolation from a reference
curve generated in the same assay with reference standards of known
concentrations of omentin-1. The color development is stopped and
the intensity of the color is measured using an automated ELISA reader
(ChroMate, 4300 Microplate Reader, Palm City FL, USA). The results
were expressed as ng/mL.2.3. Statistical analysis
Continuous variables were categorized using median values as cut-
off point. For group comparison of categorical variables, Chi-square
tests or One-Way Anova tests were used and for comparison of contin-
uous variables, Mann–Whitney U test or Kruskal-Wallis tests was ac-
complished. Overall survival (OS) was calculated from the date of ﬁrst
admission to the clinics to disease-related death or date of last contact
with the patient or any family member. Kaplan-Meier method was
used for the estimation of survival distribution and differences in OS
was assessed by the log-rank statistics. All statistical tests were carried
out two-sided and a p value ≤0.05 was considered statistically signiﬁ-
cant. Statistical analysis was carried out using SPPS 21.0 (SPSS Inc., Chi-
cago, IL., USA) software.3. Results
From February 2010 to July 2013, 33 patients with a pathologically
conﬁrmed diagnosis of PA were enrolled in this study. The baseline his-
topathological characteristics and the demographic characteristics of
the patients are listed in Table 1. The median age at diagnosis was 59
years, range 32–84 years; majority of the patients in the group were
men (n = 20, 61%). The tumor was located in the head of pancreas in
21 (64%) patients. Thirty-nine percent of 23metastatic patients who re-
ceived palliative CTx were CTx-responsive. The most common
Table 3
Results (median and range) of comparisons between the omentin marker assays and var-
ious clinical parameters.
Parameters Marker assays
n Omentin (ng/mL)
Median (range)
p
Age patients
Young (b60) 18 8.19 (3.62–219.48) 0.40
Older (N60) 15 10.48 (5.15–204.24)
Gender
Male 20 10.30 (3.62–219.48) 0.92
Female 13 9.27 (5.85–194.50)
PS
Good (0–1) 23 10.28 (3.62–219.48) 0.84
Worse (2–4) 9 9.57 (3.62–204.24)
Weight loss
Yes 26 9.93 (3.62–205.14) 0.79
No 4 74.69 (5.15–219.48)
Jaundice
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Surgerywas performed in 8 (24%) patients; 5 (15%) patients underwent
pancreaticoduodenectomy and 3 (9%) patients had palliative surgery.
The levels of serum omentin assays in patients with PA and healthy
controls are shown in Table 2. The baseline serum omentin levels were
signiﬁcantly higher in patients with PA than in the control group (medi-
an 9.57 v. 1.61 ng/mL, p b 0.001).
Table 3 shows the correlation between the serum levels omentin of
and clinico-pathological factors. Serum omentin levels were signiﬁcant-
ly higher in large pathologic tumor size comparedwith small pathologic
tumor size (p = 0.03).
The median follow-up time was 26.0 weeks (range: 1.0–184.0
weeks). At the end of the observation period, thirty-two patients
(97%) were dead. Median OS of the whole group were 41.3 ±
8.3 weeks [95% conﬁdence interval (CI) = 25–58 weeks]. While 1-
year OS rates were 24.2% (95% CI = 9.5–38.9). Older age, worse perfor-
mance status, metastatic disease, lack of liver metastases and the CTx-
unresponsiveness were found to be signiﬁcant prognostic factors
(p=0.008, p=0.002, p=0.008, p=0.02, and p=0.03, respectively).
However, serum omentin levels had no signiﬁcantly effect on OS rates
(p = 0.54) (Table 4 and Fig. 1).Yes 9 7.49 (3.62–193.88) 0.45
No 22 10.30 (3.62–219.48)
Surgery
Yes 8 7.78 (5.26–205.14) 0.75
No 25 9.42 (3.62–219.48)
Localization
Head 21 8.59 (3.62–205.14) 0.44
Corpus-tail 10 10.60 (3.62–204.24)
pT size
Small (b40 mm) 14 7.65 (3.62–193.88) 0.03⁎
Large (≥40 mm) 14 74.29 (3.62–205.14)
Metastasis
Yes 23 10.34 (3.62–219.48) 0.43
No 10 8.05 (3.62–193.88)
Liver metastasis
Yes 19 10.34 (5.26–219.48) 0.41
No 4 71.25 (3.62–188.14)
ESH
Normal 11 9.42 (3.62–219.48) 0.70
High 12 7.78 (5.37–205.14)
Hb
Low 12 10.48 (5.15–219.48) 0.08
Normal 19 7.13 (3.62–204.24)
WBC
High 9 7.78 (5.26–204.24) 0.88
Normal 22 10.30 (3.62–219.48)
PLT
Low 5 10.86 (6.63–219.48) 0.39
Normal 26 8.93 (3.62–205.14)
Albumin
Low 17 7.50 (3.62–194.50) 0.68
Normal 10 10.28 (5.15–219.48)
LDH
High 8 10.03 (5.42–204.24) 0.58
Normal 21 8.59 (3.62–219.48)4. Discussion
Although omentin-1 levels were found to be changed in some
cancers, its possible clinical signiﬁcance has remained unclear in pa-
tients with pancreatic cancer. Only a few studies have been previous-
ly performed. Both colorectal and pancreatic cancers are related with
obesity, metabolic syndrome and BMI. Recently clinical studies show
that cancers such as liver [10], prostate [12] and colorectal [11,13,16]
are associated with increases in omentin serum levels independent
of various factors such as BMI, glucose, lipid parameters, disease dif-
ferentiation [16]. In a new study, higher omentin concentrations
were associated with a higher colorectal cancer risk independent of
obesity [16].
To the best of our knowledge, there are no additional studies directly
associating the anti-inﬂammatory and tumor-suppressing effects of
omentin on other cancers. There is also no data in literature about the
relationship of serum omentin-1 levels and PA. There is only limited
data about pancreatitis and omentin levels. The elevation in omentin
levels in early stage of pancreatitis was found; it caused insulin resis-
tance and reduction in glucose levels [15].
In our study, we showed that in patients with PA, serum omentin-1
levels were elevated. Serum omentin levels were signiﬁcantly higher in
large pathologic tumor (≥4 cm) size compared with small pathologic
tumor size. This ﬁnding is really interesting.
In cancer studies, omentin was suggested to promote cancer
cell growth by triggering genomic instability and PI3K/Akt (phos-
phatidylinositol-3 kinase downstream effector) signaling pathways
and the cancer-promoting effects of omentin was independent of its
abilities to regulate obesity-inducedmetabolic risk [11,17–19]. Omentin
may also show a number of effects reﬂecting cellular immune
responses. In the area of oncologic treatments, immunooncology
is a promising topic. Maybe, omentin shows its effects as an an-
tiinﬂammatory marker.CEA
High 19 74.11 (5.42–219.48) 0.09
Normal 10 7.78 (3.62–205.14)
CA 19.9
High 22 9.95 (3.62–205.14) 0.50
Normal 7 8.59 (5.15–219.48)
Response to CTx
Yes (PR + SD) 8 7.78 (3.62–205.14) 0.71
No (PD) 7 7.41 (5.15–249.48)
⁎ p ≤ 0.05.
Table 2
The values of serummarker levels in pancreatic cancer patients and healthy controls.
Patients (n = 33) Controls (n = 30)
Marker Median Range Median Range p
Omentin (ng/mL) 9.57 3.62–219.48 1.61 0.80–4.98 b0.001⁎
⁎ p ≤ 0.05.
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omentin-1 were only a diagnostic marker in pancreatic cancer pa-
tients. However, its predictive and prognostic values were notFig. 1. Overall survival curves in pancreatic cancer patients according to serum omentin
levels (p = 0.54).
Table 4
Univariate analyses of overall survival.
Parameters Overall survival
Median (±SD) (weeks)
p
Age patients
Young 58.3 (13.1) 0.008⁎
Older 21.8 (6.6)
Gender
Male 49.9 (12.6) 0.21
Female 29.0 (7.5)
PS
Good 53.6 (10.9) 0.002⁎
Worse 15.6 (3.6)
Weight loss
Yes 36.7 (6.6) 0.34
No 74.5 (41.5)
Jaundice
Yes 41.6 (18.8) 0.46
No 41.9 (7.8)
Localization
Head 48.3 (11.8) 0.54
Corpus-tail 34.4 (10.4)
pT size
Small 42.1 (9.4) 0.37
Large 36.4 (8.9)
Metastasis
Yes 26.5 (5.9) 0.008⁎
No 76.7 (20.3)
Liver metastasis
Yes 30.0 (6.8) 0.02⁎
No 9.5 (4.6)
ESR
High 34.3 (7.7) 0.24
Normal 43.9 (12.0)
Hb
Low 41.1 (11.5) 0.66
Normal 32.1 (7.0)
WBC
High 38.2 (12.2) 0.67
Normal 34.5 (7.2)
PLT
Low 27.5 (9.0) 0.59
Normal 37.2 (7.1)
Albumin
Low 30.9 (8.8) 0.79
Normal 32.8 (8.7)
LDH
High 24.5 (12.2) 0.06
Normal 38.3 (6.8)
CEA
High 30.1 (9.4) 0.66
Normal 36.8 (7.7)
CA 19.9
High 32.5 (6.0) 0.63
Normal 40.8 (16.0)
Response to CTx
Yes 48.1 (11.4) 0.03⁎
No 23.1 (8.9)
Omentin
bMedian 41.3 (8.8) 0.54
NMedian 42.1 (14.6)
⁎ p ≤ 0.05.determined. In addition, no correlation was observed in serum
omentin level and response to chemotherapy. The small sample
size of the present study may be considered as signiﬁcant limitation
and may have inﬂuenced these results. Further studies in a larger pa-
tient population are needed.
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